Table 3.
Initial laboratory data of liver transplant recipient with SARS-CoV-2 infection
Patients tested, n (%) | Results | Patients with value, n | |
Deviation from reference (%) | |||
Blood counts, median (IQR) | |||
Leucocytes (×1000/μL) | 51 (90) | 4.50 (3.33–6.00) | 17 (33)* |
Platelets (×1000/μL) | 49 (86) | 160 (91–268) | 17 (35)* |
Lymphocytes (×1000/μL) | 49 (86) | 0.79 (0.40–1.10) | 37 (76)* |
Biochemical and liver-related test, median (IQR) | |||
AST (U/L) | 49 (86) | 38 (25–53) | 13 (26)† |
ALT (U/L) | 49 (86) | 30 (20–42) | 10 (20)† |
GGT (U/L) | 45 (79) | 66 (39–161) | 29 (64)† |
ALP (U/L) | 37 (65) | 97 (74–171) | 9 (24)† |
Total bilirubin (mg/dL) | 43 (75) | 0.70 (0.48–1.09) | 10 (23)† |
INR (ratio) | 42 (74) | 1.10 (1.03–1.28) | 14 (33)† |
Albumin (g/L) | 19 (33) | 32 (29.5–36.5) | 8 (42)* |
Creatinine (mg/dL) | 50 (88) | 1.16 (0.93–1.55) | 20 (40)† |
Glucose (mg/dL) | 36 (63.2) | 127.5 (92.5–163.0) | 24 (67)† |
Inflammatory-related markers, median (IQR) | |||
D-Dimer (ng/mL) | 17 (29.8) | 871 (380–1739) | 10 (59)† |
LDH (U/L) | 31 (54.4) | 273 (192–384) | 20 (65)† |
IL-6 (pg/L) | 9 (15.8) | 93 (59–288) | – |
Ferritin (ng/mL) | 13 (22.8) | 567 (171–1194) | 9 (69)† |
*Below reference.
†Above reference.
ALP, alanine alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase; IL-6, interleukin-6; INR, international normalised ratio; LDH, lactate dehydrogenase.